



SHEET 1 of 1

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34140ASerial No.  
09/534,376

RECEIVED

MAR 12 2003

TECH CENTER 1600/2900

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
Alitalo et al.Filing Date  
3-24-00Group  
1646

## U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date/ Publication Date	Name	Class	Subclass	Filing Date If Appropriate
EA	A19	6,403,088	6-11-02	Alitalo, et al.	424	139.1	
↓	A20	6,361,946	3-26-02	Alitalo, et al.	435	6	
	A21	20020164667	11-7-02	Alitalo, et al.	435	7.23	
↓	A22	20030026759	2-6-03	Ferrell, et al.	424	902	8-16-99

## FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

EA	C214	Enholm, B., <i>et al.</i> , "Adenoviral Expression of Vascular Endothelial Growth Factor-C Induces Lymphangiogenesis in the Skin," <i>Circ. Res.</i> , 88:623-629, 2001.
EA	C215	Hiltunen, H.O., <i>et al.</i> , "Intravascular Adenovirus-Mediated VEGF-C Gene Transfer Reduces Neointima Formation in Balloon-Benuded Rabbit Aorta," <i>Circulation</i> , 102:2262-2268, 2000.
EA	C216	Karkkainen, M. J., <i>et al.</i> , "A Model for Gene Therapy of Human Hereditary Lymphedema," <i>Proc. Natl. Acad. Sci., U.S.A.</i> , 98(22):12677-12682, 2001.

Form 10-1349 (Modified)

U.S. Department of Commerce

Patent and Trademark Office

Atty. Docket No.

28967/34140A

Serial No.

09/534,376

RECEIVED

MAR 12 2003

TECH CENTER 1600/2000

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Alitalo et al.

Filing Date

03-24-00

Group

1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

EA	C217	Saaristo, A., <i>et al.</i> , "Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes," <i>FASEB J.</i> , 16:1041-1049, 2002.
EA	C218	Saaraisto, A., <i>et al.</i> , "Lymphangiogenic Gene Therapy With Minimal Blood Vascular Side Effects," <i>J. Exp. Med.</i> , 196(6):719-730, 2002.

EXAMINER

Eileen B. O'Hara

DATE CONSIDERED

5/16/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SHEET 1 of 1

U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 28967/34140A	Serial No. 09/534,376
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>			
		Applicant Alitalo et al.	
		Filing Date 3-24-00	Group 1632

## U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
EPA	A18	6,451,764	09/17/02	Lee, et al.	514	12	

## FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)


EXAMINER <i>Eileen B. O'Hara</i>	DATE CONSIDERED <i>5/16/03</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED

NOV 05 2002

TECH CENTER 1600/2900